Ad
related to: rnase-l inhibitor medications list printable
Search results
Results from the WOW.Com Content Network
Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of DNA). Examples include: motexafin gadolinium. [1] hydroxyurea [2] fludarabine, cladribine, gemcitabine, tezacitabine, and triapine [3] gallium maltolate ...
6059 24015 Ensembl ENSG00000164163 ENSMUSG00000058355 UniProt P61221 P61222 RefSeq (mRNA) NM_002940 NM_001040876 NM_015751 RefSeq (protein) NP_001035809 NP_002931 NP_056566 Location (UCSC) Chr 4: 145.1 – 145.13 Mb Chr 8: 80.41 – 80.44 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse ATP-binding cassette sub-family E member 1 (ABCE1) also known as RNase L inhibitor (RLI) is an ...
Ribonuclease L or RNase L (for latent), known sometimes as ribonuclease 4 or 2'-5' oligoadenylate synthetase-dependent ribonuclease, is an interferon (IFN)-induced ribonuclease which, upon activation, destroys all RNA within the cell (both cellular and viral) as well as inhibiting mRNA export.
Antisense drugs are being developed to treat lung cancer, diabetes and diseases such as arthritis and asthma with a major inflammatory component. [67] It shows that the decreased expression of MLLT4 antisense RNA 1 (MLLT4‑AS1) is a potential biomarker and a predictor of a poor prognosis for gastric cancer.
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. [1]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Ribonuclease inhibitor (RI) is a large (~450 residues, ~49 kDa), acidic (pI ~4.7), leucine-rich repeat protein that forms extremely tight complexes with certain ribonucleases. It is a major cellular protein, comprising ~0.1% of all cellular protein by weight, and appears to play an important role in regulating the lifetime of RNA .
Antifolates act primarily as inhibitors of both RNA and DNA, and are often grouped with nucleic acid inhibitors in textbooks. However, they also act indirectly as protein synthesis inhibitors (because tetrahydrofolate is also involved in the synthesis of amino acids serine and methionine), so they are sometimes considered as their own category, antimetabolites. [6]
Ad
related to: rnase-l inhibitor medications list printable